Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy
Open accessThe DOI matches its Crossref record; 154 of the 154 references it cites were found in a registry or an index.
Abstract
Deficiency in DNA damage response (DDR) genes leads to impaired DNA repair functions that will induce genomic instability and facilitate cancer development. However, alterations of DDR genes can serve as biomarkers for the selection of suitable patients to receive specific therapeutics, such as immune checkpoint blockade (ICB) therapy. In addition, certain altered DDR genes can be ideal therapeutic targets through adapting the mechanism of synthetic lethality. Recent studies indicate that targeting DDR can improve cancer immunotherapy by modulating the immune response mediated by cGAS-STING-interferon signaling. Investigations of the interplay of DDR-targeting and ICB therapies provide more effective treatment options for cancer patients. This review introduces the mechanisms of DDR and discusses their crucial roles in cancer therapy based on the concepts of synthetic lethality and ICB. The contemporary clinical trials of DDR-targeting and ICB therapies in breast, colorectal, and pancreatic cancers are included.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 (A) DNA repair systems. Different DNA damages are recognized and repaired through different DNA repair pathways. DNA damages shown here includes ultraviolent light (UV)-induced cyclobutane pyrimidine dimers (TT), benzo[a]pyrene (BaP)-induced bulky DNA adducts, DNA interstrand crosslink, deamination (-NH3, GC to GU pairing), reactive oxygen species (ROS) induced 8-oxoguanine, mismatch DNA pairing (e.g., AG pairing), double-strand breaks (DSBs) induced by ionized radiation, X-ray or cisplatin. Except for direct repair, nucleotide excision repair (NER), base excision repair (BER), mismatch repair (MMR), homologous recombination (HR) and non-homologous end-joining (NHEJ) are shown here. Each DNA repair mechanism comprises three main procedures: recognition, excision, and polymerization. The red circle indicates the defective mutations found in hereditary nonpolyposis colorectal cancer (HNPCC), colorectal cancer (CRC), breast cancer (BC), ovary cancer (OC) and pancreatic cancer (PC). (B) The DNA damage response (DDR). ATM and ATR are activated by DSBs and single-strand breaks. The activated ATM and ATR phosphorylate downstream cell cycle checkpoint kinases, CHK1 and CHK2, which then phosphorylate p53, CDC25, and WEE1. The phosphorylated p53 increases the expression of p21, a potent CDK inhibitor. Phosphorylation of CDC25 (inactive) and WEE1 (active) results in inhibition of CDK activity and leads to cell cycle arrest at G1/S and G2/M transition. Graph created with Biorender.com.](https://figures.cochat.ai/paper-figures/89829d6563874fbf876453a198f74e82/targeting-dna-damage-response-and-immune-checkpoint-for-anticancer-therapy-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Defective DDR can also cause changes in the TME by releasing inflammatory cytokines, which create an immunosuppressive state that helps CRC cells evade immune surveillance, thereby reducing the effectiveness of immunotherapies [51].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [51]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the inherent genomic instability of CRC cells leads to the accumulation of mutations potentially resulting in drug-resistant clones that can expand under treatment [51].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“PARP inhibitors such as olaparib can be effective in cancers with defects in homologous recombination repair and are currently approved for several cancers harboring BRCA mutations, including breast, ovarian, pancreatic, and prostate cancers [51].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [51]
The cited source says what the claim attributes to it.
In the citing paper
“Currently, there are several DDR inhibitors targeting ATM, ATR, DNA-PK, CHK1, or WEE1 being investigated for treating various cancers, including CRC [51].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · cited 1×
“Cancer is the major leading cause of death worldwide, accounting for nearly ten million deaths in 2020 [1].”
BackgroundHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“Considering the differences between cancerous and normal cells, Hanahan and Weinberg define important hallmarks of cancer, which include autonomous growth signal, evasion of growth inhibitory signal, evasion of apoptosis, unlimited replicative potential, angiogenesis, invasion and metastasis, reprograming energy metab…”
BackgroundHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · cited 1×
“Thus, BRCA1- or BRCA2mutated cancer cells exhibit an increased sensitivity to PARP inhibitors when compared to normal cells [38,56,57] (Figure 3A).”
BackgroundMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 2×
“Functional analysis in a responding patient demonstrated rapid in vivo expansion of neoantigen-specific T cell clones that were reactive to cancer’s mutant neoantigen [129].”
BackgroundPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198 · cited 1×
“Thus, BRCA1- or BRCA2mutated cancer cells exhibit an increased sensitivity to PARP inhibitors when compared to normal cells [38,56,57] (Figure 3A).”
BackgroundCyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Sun, L., Wu, J., Du, F., Chen, X., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1232458 · Cited by 4,996 · cited 1×
“The binding of cGAMP to STING activates downstream signaling molecules include TANK-binding kinase 1 (TBK1)/interferon regulatory factor 3 (IRF3) and IKKα/β/NFκB to produce type I IFN (IFN-I), IFN-stimulated genes (ISGs), and pro-inflammatory cytokines, such as TNF-α [77,78].”
BackgroundGenome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939 · cited 2×
“Germline mutations of NER genes, such as Xeroderma pigmentosum (XP) family genes, are associated with increased cancer incidence in the affected patients [9,32].”
BackgroundFive-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723 · cited 1×
“For metastatic melanoma as an example, patient’s long-term survival rate can be extended from 5% to 50% with anti-PD-1 plus anti-CTLA-4 combination therapy [92].”
BackgroundInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling
Ishikawa, H., & Barber, G. N. (2008) · Nature · doi:10.1038/nature07317 · Cited by 3,576 · cited 1×
“The binding of cGAMP to STING activates downstream signaling molecules include TANK-binding kinase 1 (TBK1)/interferon regulatory factor 3 (IRF3) and IKKα/β/NFκB to produce type I IFN (IFN-I), IFN-stimulated genes (ISGs), and pro-inflammatory cytokines, such as TNF-α [77,78].”
BackgroundOlaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,880 · cited 1×
“Thus, BRCA1- or BRCA2mutated cancer cells exhibit an increased sensitivity to PARP inhibitors when compared to normal cells [38,56,57] (Figure 3A).”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Dysregulation of DNA damage response (DDR) is an important driver of genomic instability [9,10]; in contrast, alterations of DDR genes can be biomarkers and therapeutic targets for cancer treatment [11–13].”
BackgroundWhole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642 · cited 1×
“The DDR deficiency occurs in up to 24% pancreatic cancer [49,136].”
BackgroundMicrosatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456 · cited 1×
“These mutations cause dMMR in sporadic and hereditary CRC, in which abnormal lengths of dinucleotide repeat sequences, a representative of MSI, are found in a high frequency (~15%) [124].”
BackgroundCTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360 · cited 2×
“High-expression of CTLA-1, PD-L1, and PD-L2 immune checkpoint molecules in cancer cells is an important mechanism underlying immune escape of cancer cells [88].”
BackgroundMaintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302 · cited 2×
“The results show that olaparib increases PFS when compared with placebo [142].”
BackgroundNiraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
González-Martín, A., Pothuri, B., Vergote, I., DePont Christensen, R., Graybill, W., Mirza, M. R., McCormick, C., Lorusso, D., Hoskins, P., Freyer, G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910962 · Cited by 2,263 · cited 1×
“In line with this notion, many studies have found that some HRD-negative patients also respond to PARP inhibitors [60,146,147].”
ResultCD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175 · cited 2×
“Monotherapy DDRi or ICI (molecular selection) Talazoparib PARP aBC and/or mBC 11 Germline BRCAm NCT01945775 Approved EMBRACA trial [115,116] Olaparib PARP mBC Germline BRCAm NCT02000622 Approved OlympiAD trial [117] Pembrolizumab PD-1 mBC, etc.”
BackgroundOlaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Ray-Coquard, I., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Berger, R., Fujiwara, K., Vergote, I., Colombo, N., Mäenpää, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911361 · Cited by 2,055 · cited 1×
“In line with this notion, many studies have found that some HRD-negative patients also respond to PARP inhibitors [60,146,147].”
ResultATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response
Blackford, A. N., & Jackson, S. P. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.05.015 · Cited by 1,961 · cited 1×
“Upon DNA damage, cells can detect DNA lesions through several sensors and kinases, such as ataxia telangiectasia mutated (ATM), ataxia telangiectasia and Rad3-related (ATR), and DNA-dependent protein kinase (DNA-PK), to launch DDR [18].”
BackgroundImmunotherapy in colorectal cancer: Rationale, challenges and potential
Ganesh, K., Stadler, Z. K., Cercek, A., Mendelsohn, R. B., Shia, J., Segal, N. H., & Diaz, L. A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0126-x · Cited by 1,954 · cited 1×
“FDA has approved pembrolizumab to treat MSI-H or dMMR solid tumors including CRC [101,102,126].”
BackgroundInterferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942 · cited 1×
“These IFN-induced immune responses are crucial for the killing of cancer cells; thus, IFN response induced by DDR targeting (PARPness) can enhance the efficacy of cancer immunotherapy [80,81].”
BackgroundThe multifaceted roles of PARP1 in DNA repair and chromatin remodelling
Ray Chaudhuri, A., & Nussenzweig, A. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.53 · Cited by 1,786
DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy
Olaussen, K. A., Dunant, A., Fouret, P., Brambilla, E., André, F., Haddad, V., Taranchon, E., Filipits, M., Pirker, R., Popper, H. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060570 · Cited by 1,727 · cited 1×
“In NSCLC, low expression of ERCC1 predicts a better outcome in patients who receive platinum-based chemotherapy due to inefficient NER and increased apoptosis of tumor cells [33,34].”
BackgroundCTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666 · cited 5×
“The repair process comprises three steps (recognition, excision, and polymerization) to fix the DNA lesions [27,31].”
BackgroundInfluentialHallmarks of 'BRCAness' in sporadic cancers
Turner, N., Tutt, A., & Ashworth, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1457 · Cited by 1,657
The DNA damage response and cancer therapy
Lord, C. J., & Ashworth, A. (2012) · Nature · doi:10.1038/nature10760 · Cited by 1,649 · cited 2×
“There are several inhibitors of ATM, ATR, CHK1, DNA-PK, WEE1 are under clinical development for treating solid tumors and lymphoma [29,44,70].”
BackgroundEncorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491 · cited 1×
“Nowadays, dozens of target therapeutics have been approved to treat various cancers, including colorectal cancer (CRC), breast cancer (BC), melanoma, non-small cell lung cancer (NSCLC), leukemia, and so on [6,7].”
BackgroundChalabi, M., Fanchi, L. F., Dijkstra, K. K., Van den Berg, J. G., Aalbers, A. G., Sikorska, K., Lopez-Yurda, M., Grootscholten, C., Beets, G. L., Snaebjornsson, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0805-8 · Cited by 1,417 · cited 2×
“Nivolumab Ipilimumab PD-1 CTLA-4 Celecoxib (COX-2i) mCRC 9 MSI, MSS NCT03026140 II NICHE trial [130]”
BackgroundMechanisms of resistance to immune checkpoint inhibitors
Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383 · cited 9×
“A growing body of evidence demonstrates that targeting DDR is an attractive strategy to promote inflammation in TIME, which Int.”
BackgroundInfluentialThe multifaceted mismatch-repair system
Jiricny, J. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1907 · Cited by 1,370 · cited 1×
“High levels of MSI (MSI-H) have been found in many different types of cancer [40,41].”
BackgroundPARP inhibition: PARP1 and beyond
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298 · cited 1×
“Then, the poly(ADP-ribose) polymerase 1 (PARP1) binds to BER intermediates and transfers poly(ADP-ribose) to DNA, BER effectors, and histones (PARylation) for recruiting XRCC1 and polymerase β to repair the aberrant nucleotides [35,36].”
BackgroundThe Cytosolic DNA-Sensing cGAS–STING Pathway in Cancer
Kwon, J., & Bakhoum, S. F. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0761 · Cited by 1,293
Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage
Falck, J., Coates, J., & Jackson, S. P. (2005) · Nature · doi:10.1038/nature03442 · Cited by 1,258
Schmid, P., Rugo, H. S., Adams, S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Henschel, V., Molinero, L., Chui, S. Y., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30689-8 · Cited by 1,216 · cited 1×
“Monotherapy DDRi or ICI CT (nP) 9 Atezolizurmab PD-L1 Untreated mTNBC NCT02425891 III IMpassion 130 trial [114] CT (nP) v.”
BackgroundUnderstanding nucleotide excision repair and its roles in cancer and ageing
Marteijn, J. A., Lans, H., Vermeulen, W., & Hoeijmakers, J. H. J. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3822 · Cited by 1,192 · cited 1×
“Germline mutations of NER genes, such as Xeroderma pigmentosum (XP) family genes, are associated with increased cancer incidence in the affected patients [9,32].”
BackgroundDNA damage and the balance between survival and death in cancer biology
Roos, W. P., Thomas, A. D., & Kaina, B. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.2 · Cited by 1,189
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189 · cited 2×
“Notably, some studies have shown that targeting oncogenic pathways or epigenetic modifiers can improve the efficacies of DDR and immune checkpoint inhibitors [13,14,149].”
BackgroundDufour, J. H., Dziejman, M., Liu, M. T., Leung, J. H., Lane, T. E., & Luster, A. D. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.7.3195 · Cited by 1,075 · cited 8×
“A growing body of evidence demonstrates that targeting DDR is an attractive strategy to promote inflammation in TIME, which Int.”
BackgroundInfluentialDNA repair dysregulation from cancer driver to therapeutic target
Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051 · cited 6×
“The repair process comprises three steps (recognition, excision, and polymerization) to fix the DNA lesions [27,31].”
BackgroundInfluentialVeliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
Coleman, R. L., Fleming, G. F., Brady, M. F., Swisher, E. M., Steffensen, K. D., Friedlander, M., Okamoto, A., Moore, K. N., Efrat Ben-Baruch, N., Werner, T. L., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1909707 · Cited by 913 · cited 1×
“In line with this notion, many studies have found that some HRD-negative patients also respond to PARP inhibitors [60,146,147].”
ResultAntitumour actions of interferons: implications for cancer therapy
Parker, B. S., Rautela, J., & Hertzog, P. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.14 · Cited by 907
Sen, T., Rodriguez, B. L., Chen, L., Corte, C. M. D., Morikawa, N., Fujimoto, J., Cristea, S., Nguyen, T., Diao, L., Li, L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1020 · Cited by 902 · cited 1×
“The cGASSTING signaling can contribute to ICI-based therapy in DDR-altered tumors [76,82,103].”
BackgroundHomologous Recombination and Human Health: The Roles of BRCA1, BRCA2, and Associated Proteins
Prakash, R., Zhang, Y., Feng, W., & Jasin, M. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016600 · Cited by 869 · cited 1×
“The resected single-strand DNA protrusion is protected by RPA and then can invade into the complementary sister chromatid DNA by the assistance of RAD51, BRCA2, and Partner And Localizer Of BRCA2 (PALB2) for HR [47].”
BackgroundExomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
Jones, S., Hruban, R. H., Kamiyama, M., Borges, M., Zhang, X., Parsons, D. W., Lin, J. C.-H., Palmisano, E., Brune, K., Jaffee, E. M., et al. (2009) · Science · doi:10.1126/science.1171202 · Cited by 826
Robson, M. E., Tung, N., Conte, P., Im, S.-A., Senkus, E., Xu, B., Masuda, N., Delaloge, S., Li, W., Armstrong, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz012 · Cited by 779 · cited 1×
“The olaparib has been approved by FDA for gBRCAm, HER2-negative metastatic breast cancer and ovary cancer [72,121,122].”
BackgroundMGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Weller, M., Stupp, R., Reifenberger, G., Brandes, A. A., van den Bent, M. J., Wick, W., & Hegi, M. E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.197 · Cited by 778 · cited 1×
“Low expression or promoter hypermethylation of MGMT is correlated with a favorable outcome of glioblastoma patients who received temozolomide, because these cancer cells are unable to efficiently repair temozolomide-induced alkylations [28,29].”
BackgroundA decade of clinical development of PARP inhibitors in perspective
Mateo, J., Lord, C. J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S. B., & de Bono, J. S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz192 · Cited by 743
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
Pommier, Y., O’Connor, M. J., & de Bono, J. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf9246 · Cited by 739
LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade
Sheng, W., LaFleur, M. W., Nguyen, T. H., Chen, S., Chakravarthy, A., Conway, J. R., Li, Y., Chen, H., Yang, H., Hsu, P.-H., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.052 · Cited by 693
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
Wheeler, D. L., Dunn, E. F., & Harari, P. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.97 · Cited by 683 · cited 1×
“However, not all patients are eligible to target therapy and drug resistance remains a problem to be overcome [8].”
BackgroundFirst FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
Lemery, S., Keegan, P., & Pazdur, R. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1709968 · Cited by 664 · cited 3×
“As described above, only a subgroup of patients with specific genetic contexts (dMMR/ MSI-H) have a better response rate to ICB therapy [101,102].”
BackgroundBRCA1 and BRCA2 and the genetics of breast and ovarian cancer
Welcsh, P. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.705 · Cited by 648 · cited 1×
“In HRR pathway, germline or somatic BRCA1 and BRCA2 mutations are associated with increased risks of solid tumors, especially breast and ovary cancers [48].”
BackgroundcGAS-STING, an important pathway in cancer immunotherapy
Jiang, M., Chen, P., Wang, L., Li, W., Chen, B., Liu, Y., Wang, H., Zhao, S., Ye, L., He, Y., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00916-z · Cited by 647
DNA Damage and Repair Biomarkers of Immunotherapy Response
Mouw, K. W., Goldberg, M. S., Konstantinopoulos, P. A., & D'Andrea, A. D. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0226 · Cited by 645 · cited 2×
“The tumor-intrinsic DDR status, such as tumor mutational burden (TMB), MSI, dMMR, or HRD, can also influence the efficacy of ICI-based immunotherapy [22,25,82].”
BackgroundIbrahim, Y. H., García-García, C., Serra, V., He, L., Torres-Lockhart, K., Prat, A., Anton, P., Cozar, P., Guzmán, M., Grueso, J., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0348 · Cited by 601
Therapeutic opportunities within the DNA damage response
Pearl, L. H., Schierz, A. C., Ward, S. E., Al-Lazikani, B., & Pearl, F. M. G. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3891 · Cited by 587 · cited 1×
“Cells have invested several DNA repair systems to deal with different kinds of DNA damages [26] (Figure 2A).”
BackgroundIpilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
Lipson, E. J., & Drake, C. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1595 · Cited by 570 · cited 1×
“In 2011, FDA has approved the anti-CTLA-4 mAb (ipilimumab) for treating melanomas [91].”
BackgroundcGAS is essential for the antitumor effect of immune checkpoint blockade
Wang, H., Hu, S., Chen, X., Shi, H., Chen, C., Sun, L., & Chen, Z. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1621363114 · Cited by 563 · cited 3×
“The cGASSTING signaling can contribute to ICI-based therapy in DDR-altered tumors [76,82,103].”
BackgroundKonstantinopoulos, P. A., Waggoner, S., Vidal, G. A., Mita, M., Moroney, J. W., Holloway, R., Van Le, L., Sachdev, J. C., Chapman-Davis, E., Colon-Otero, G., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1048 · Cited by 563 · cited 2×
“The combination therapy has a tolerable safety profile [110,111].”
BackgroundEpigenetic therapy in immune-oncology
Jones, P. A., Ohtani, H., Chakravarthy, A., & De Carvalho, D. D. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0109-9 · Cited by 550 · cited 11×
“For example, deficiency in BRCA1 or BRCA2 gene is observed to be associated with improved response to ICIs in patients with biliary tract cancer or hepatocellular carcinoma [16,17].”
BackgroundInfluentialKim, G., Ison, G., McKee, A. E., Zhang, H., Tang, S., Gwise, T., Sridhara, R., Lee, E., Tzou, A., Philip, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0887 · Cited by 528 · cited 1×
“Olaparib is the first FDA approved PARP small molecule inhibitor for BRCA1- and BRCA2-mutated cancers [64,65].”
BackgroundExploring and comparing adverse events between PARP inhibitors
LaFargue, C. J., Dal Molin, G. Z., Sood, A. K., & Coleman, R. L. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30786-1 · Cited by 487
Domchek, S. M., Postel-Vinay, S., Im, S.-A., Park, Y. H., Delord, J.-P., Italiano, A., Alexandre, J., You, B., Bastian, S., Krebs, M. G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30324-7 · Cited by 484 · cited 2×
“Combination Olaparib PARP Durvalumab PD-L1 Metastatic HER2- BC 1 Germline BRCAm 2 NCT02734004 II MEDIOLA trial [109] Niraparib PARP Pembrolizumab PD-1 aTNBC 3 or mTNBC 4 BRCAm NCT02657889 II TOPACIO trial [111] Talazoparib PARP Avelumab PD-L1 aBC 5 NCT03964532 I/II TALAVE trial [112] Olaparib PARP Atezolizurmab PD-L1…”
BackgroundVinayak, S., Tolaney, S. M., Schwartzberg, L., Mita, M., McCann, G., Tan, A. R., Wahner-Hendrickson, A. E., Forero, A., Anders, C., Wulf, G. M., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1029 · Cited by 454 · cited 1×
“The combination therapy has a tolerable safety profile [110,111].”
BackgroundWang, F., Zhao, Q., Wang, Y.-N., Jin, Y., He, M.-M., Liu, Z.-X., & Xu, R.-H. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2963 · Cited by 436 · cited 1×
“POLE, POLD1 have been considered as predictive biomarkers for immunotherapy in many cancer types, including melanoma, colorectal, and endometrial cancers [123].”
BackgroundSTING: a master regulator in the cancer-immunity cycle
Zhu, Y., An, X., Zhang, X., Qiao, Y., Zheng, T., & Li, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1087-y · Cited by 431
Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy
Li, A., Yi, M., Qin, S., Song, Y., Chu, Q., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0721-x · Cited by 413
Litton, J. K., Hurvitz, S. A., Mina, L. A., Rugo, H. S., Lee, K.-H., Gonçalves, A., Diab, S., Woodward, N., Goodwin, A., Yerushalmi, R., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2098 · Cited by 412 · cited 1×
“Although talazoparib significantly improves progression-free survival (PFS) over chemotherapy [115], it does not show superior effect on patient’s OS [120].”
BackgroundThe molecular basis and disease relevance of non-homologous DNA end joining
Zhao, B., Rothenberg, E., Ramsden, D. A., & Lieber, M. R. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00297-8 · Cited by 384 · cited 2×
“Next, the processed broken ends are joined together by the DNA ligase 4/XRCC4 complex [45].”
BackgroundThe Landscape of Microsatellite Instability in Colorectal and Endometrial Cancer Genomes
Kim, T.-M., Laird, P. W., & Park, P. J. (2013) · Cell · doi:10.1016/j.cell.2013.10.015 · Cited by 380 · cited 2×
“High levels of MSI (MSI-H) have been found in many different types of cancer [40,41].”
BackgroundDual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC
Le, X., Nilsson, M., Goldman, J., Reck, M., Nakagawa, K., Kato, T., Ares, L. P., Frimodt-Moller, B., Wolff, K., Visseren-Grul, C., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.10.006 · Cited by 339 · cited 1×
“For examples, cell growth and angiogenesis signalings mediated by epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) pathways are identified as the main molecular targets of tyrosine kinase inhibitors (TKIs) (Figure 1B) [4,5].”
BackgroundWatkins, J. A., Irshad, S., Grigoriadis, A., & Tutt, A. N. (2014) · Breast Cancer Research · doi:10.1186/bcr3670 · Cited by 327 · cited 1×
“It is estimated that around 5–10% of breast cancers are inherited with gene mutations, which include germline mutations of BRCA1, BRCA2, and other DDR genes [55,108].”
BackgroundJiang, M., Jia, K., Wang, L., Li, W., Chen, B., Liu, Y., Wang, H., Zhao, S., He, Y., & Zhou, C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.01.003 · Cited by 320 · cited 1×
“DDR and immune biomarkers, such as HRD, TMB-high, MSI-H, dMMR, and expression of immune checkpoint molecules [22,24,25].”
BackgroundDNA Damage and Cancer Immunotherapy: A STING in the Tale
Reisländer, T., Groelly, F. J., & Tarsounas, M. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.07.026 · Cited by 314 · cited 2×
“Therefore, elucidating the relationship between tumor-intrinsic DDR characteristics and ICI efficacies can improve the development of precision cancer immunotherapy [23,80,106].”
BackgroundKarzai, F., VanderWeele, D., Madan, R. A., Owens, H., Cordes, L. M., Hankin, A., Couvillon, A., Nichols, E., Bilusic, M., Beshiri, M. L., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0463-2 · Cited by 309
Sun, C., Yin, J., Fang, Y., Chen, J., Jeong, K. J., Chen, X., Vellano, C. P., Ju, Z., Zhao, W., Zhang, D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.019 · Cited by 300 · cited 1×
“Therefore, combination of PARP and BRD4 inhibitors can induce synthetic lethality in HR-proficient cancers [67,68].”
BackgroundDomchek, S. M., Aghajanian, C., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmaña, J., Mitchell, G., Fried, G., Stemmer, S. M., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.12.020 · Cited by 297 · cited 2×
“The results in gBRCAm ovary cancer patients show notable antitumor activity and durable responses [121,143].”
BackgroundFlaherty, K. T., Gray, R. J., Chen, A. P., Li, S., McShane, L. M., Patton, D., Hamilton, S. R., Williams, P. M., Iafrate, A. J., Sklar, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03010 · Cited by 294 · cited 2×
“Molecular Match Nivolumab PD-1 PC, BC 6, CRC MLH1, MSH2, NCT02465060 II [137] Adavosertib WEE1 BRCA1/2 NCI match trail”
BackgroundTargeting DNA damage response in cancer therapy
Hosoya, N., & Miyagawa, K. (2014) · Cancer Science · doi:10.1111/cas.12366 · Cited by 294
Targeting the DNA damage response in immuno-oncology: developments and opportunities
Chabanon, R. M., Rouanne, M., Lord, C. J., Soria, J.-C., Pasero, P., & Postel-Vinay, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00386-6 · Cited by 293 · cited 2×
“Notably, some studies have shown that targeting oncogenic pathways or epigenetic modifiers can improve the efficacies of DDR and immune checkpoint inhibitors [13,14,149].”
BackgroundDNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity
Lu, C., Guan, J., Lu, S., Jin, Q., Rousseau, B., Lu, T., Stephens, D., Zhang, H., Zhu, J., Yang, M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.006 · Cited by 285
PALB2 mutations in European familial pancreatic cancer families
Slater, E., Langer, P., Niemczyk, E., Strauch, K., Butler, J., Habbe, N., Neoptolemos, J., Greenhalf, W., & Bartsch, D. (2010) · Clinical Genetics · doi:10.1111/j.1399-0004.2010.01425.x · Cited by 278
Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system
Lhuillier, C., Rudqvist, N.-P., Elemento, O., Formenti, S. C., & Demaria, S. (2019) · Genome Medicine · doi:10.1186/s13073-019-0653-7 · Cited by 276 · cited 1×
“Radiotherapy not only generates cytotoxic DNA damage but also induces tumorspecific immune response, which enhances anticancer efficacy [95].”
BackgroundQuigley, D., Alumkal, J. J., Wyatt, A. W., Kothari, V., Foye, A., Lloyd, P., Aggarwal, R., Kim, W., Lu, E., Schwartzman, J., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0146 · Cited by 273 · cited 1×
“Indeed, secondary mutations of BRCA1/2 genes that restore HRR function are found in patient’s circulating cell-free DNA [153].”
BackgroundCytosolic DNA sensing by cGAS: regulation, function, and human diseases
Yu, L., & Liu, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00554-y · Cited by 269 · cited 1×
“The cyclic GMP-AMP synthase (cGAS) is one of the major PRRs to detect cytosolic DNA in cancer cells [75,76].”
BackgroundPARP inhibitors in the management of breast cancer: current data and future prospects
Livraghi, L., & Garber, J. E. (2015) · BMC Medicine · doi:10.1186/s12916-015-0425-1 · Cited by 269
Lim, J. Y. H., Gerber, S. A., Murphy, S. P., & Lord, E. M. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1506-7 · Cited by 257 · cited 8×
“A growing body of evidence demonstrates that targeting DDR is an attractive strategy to promote inflammation in TIME, which Int.”
BackgroundInfluentialChallenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy
Motedayen Aval, L., Pease, J. E., Sharma, R., & Pinato, D. J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103323 · Cited by 248
Applying Synthetic Lethality for the Selective Targeting of Cancer
McLornan, D. P., List, A., & Mufti, G. J. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1407390 · Cited by 239 · cited 1×
“Nowadays, induction of synthetic lethality in cancer cells has become a promising strategy in cancer therapy [13,71].”
BackgroundPark, W., Chen, J., Chou, J. F., Varghese, A. M., Yu, K. H., Wong, W., Capanu, M., Balachandran, V., McIntyre, C. A., El Dika, I., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0418 · Cited by 237 · cited 2×
“The DDR deficiency occurs in up to 24% pancreatic cancer [49,136].”
BackgroundThe Impact of Radiation-Induced DNA Damage on cGAS-STING-Mediated Immune Responses to Cancer
Storozynsky, Q., & Hitt, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228877 · Cited by 228
Gourley, C., Balmaña, J., Ledermann, J. A., Serra, V., Dent, R., Loibl, S., Pujade-Lauraine, E., & Boulton, S. J. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02050 · Cited by 194
Tischkowitz, M. D., Sabbaghian, N., Hamel, N., Borgida, A., Rosner, C., Taherian, N., Srivastava, A., Holter, S., Rothenmund, H., Ghadirian, P., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.055 · Cited by 189
Sabnis, A. J., & Bivona, T. G. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.12.009 · Cited by 189 · cited 2×
“Nowadays, dozens of target therapeutics have been approved to treat various cancers, including colorectal cancer (CRC), breast cancer (BC), melanoma, non-small cell lung cancer (NSCLC), leukemia, and so on [6,7].”
BackgroundArora, S., Balasubramaniam, S., Zhang, H., Berman, T., Narayan, P., Suzman, D., Bloomquist, E., Tang, S., Gong, Y., Sridhara, R., et al. (2021) · The Oncologist · doi:10.1002/onco.13551 · Cited by 180 · cited 2×
“PARP inhibitors can also be combined with traditional anticancer therapeutics [72] (Figure 3B).”
BackgroundLloyd, R. L., Wijnhoven, P. W. G., Ramos-Montoya, A., Wilson, Z., Illuzzi, G., Falenta, K., Jones, G. N., James, N., Chabbert, C. D., Stott, J., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1328-y · Cited by 179 · cited 1×
“Similarly, inhibition of other HRR genes, such as ATM and ATR, leads to BRCAness and sensitizes cancer cells to PARP inhibitors [69].”
BackgroundBRCA1 Directs the Repair Pathway to Homologous Recombination by Promoting 53BP1 Dephosphorylation
Isono, M., Niimi, A., Oike, T., Hagiwara, Y., Sato, H., Sekine, R., Yoshida, Y., Isobe, S.-Y., Obuse, C., Nishi, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.042 · Cited by 178 · cited 1×
“The MRN complex, C-terminal binding protein interacting protein (CtIP), exonuclease EXO1, and BRCA1 are involved in DNA resection and 53BP1 de-phosphorylation [46].”
BackgroundDefining and Modulating ‘BRCAness’
Byrum, A. K., Vindigni, A., & Mosammaparast, N. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.06.005 · Cited by 167 · cited 1×
“In addition to BRCA1 and BRCA2, mutations of other HRR genes that cause HRD may also confer a phenotype (BRCAness) similar as that of BRCA mutations [59].”
BackgroundMatulonis, U. A., Penson, R. T., Domchek, S. M., Kaufman, B., Shapira-Frommer, R., Audeh, M. W., Kaye, S., Molife, L. R., Gelmon, K. A., Robertson, J. D., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw133 · Cited by 160 · cited 2×
“The results in gBRCAm ovary cancer patients show notable antitumor activity and durable responses [121,143].”
BackgroundLowery, M. A., Kelsen, D. P., Capanu, M., Smith, S. C., Lee, J. W., Stadler, Z. K., Moore, M. J., Kindler, H. L., Golan, T., Segal, A., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2017.11.004 · Cited by 156 · cited 2×
“The results show no confirmed response, suggesting that development of other therapeutics are needed for the pancreatic cancer patients with BRCA1/2 or PALB2 mutations [139].”
BackgroundPrasad, V. K., Kaestner, V., & Mailankody, S. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4182 · Cited by 144 · cited 3×
“As described above, only a subgroup of patients with specific genetic contexts (dMMR/ MSI-H) have a better response rate to ICB therapy [101,102].”
BackgroundEttl, J., Quek, R. G. W., Lee, K.-H., Rugo, H. S., Hurvitz, S., Gonçalves, A., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy257 · Cited by 143 · cited 1×
“Monotherapy DDRi or ICI (molecular selection) Talazoparib PARP aBC and/or mBC 11 Germline BRCAm NCT01945775 Approved EMBRACA trial [115,116] Olaparib PARP mBC Germline BRCAm NCT02000622 Approved OlympiAD trial [117] Pembrolizumab PD-1 mBC, etc.”
BackgroundRole of POLE and POLD1 in familial cancer
Mur, P., García-Mulero, S., del Valle, J., Magraner-Pardo, L., Vidal, A., Pineda, M., Cinnirella, G., Martín-Ramos, E., Pons, T., López-Doriga, A., et al. (2020) · Genetics in Medicine · doi:10.1038/s41436-020-0922-2 · Cited by 140 · cited 1×
“These trials select CRC patients according to POLE mutations, which have been reported in colorectal and various cancers [131].”
BackgroundNgoi, N. Y. L., & Tan, D. S. P. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100144 · Cited by 139 · cited 1×
“Although FDA has approved the two HRD diagnostic tests, myChoice CDx and FoundationOne CDx, some problems remain to be solved, such as the determination of proper thresholds for HRD scores, which will influence the classification of patients with or without HRD phenotype [145].”
MethodJuliá, E. P., Amante, A., Pampena, M. B., Mordoh, J., & Levy, E. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02140 · Cited by 139 · cited 2×
“Combination Olaparib PARP Durvalumab PD-L1 Metastatic HER2- BC 1 Germline BRCAm 2 NCT02734004 II MEDIOLA trial [109] Niraparib PARP Pembrolizumab PD-1 aTNBC 3 or mTNBC 4 BRCAm NCT02657889 II TOPACIO trial [111] Talazoparib PARP Avelumab PD-L1 aBC 5 NCT03964532 I/II TALAVE trial [112] Olaparib PARP Atezolizurmab PD-L1…”
BackgroundMarkham, A., & Keam, S. J. (2020) · Drugs · doi:10.1007/s40265-020-01331-x · Cited by 134 · cited 1×
“This is an open-label, phase 2 study to assess the efficacy of a genomic-driven maintenance therapy in terms of PFS in 307 pancreatic cancer patients in three groups: olaparib for BRCAness (arm A), and randomization of durvalumab plus selumetinib (MEK inhibitor) [144] (arm B) or FOLFIRI (folinic acid, fluorouracil and…”
Seligmann, J. F., Fisher, D. J., Brown, L. C., Adams, R. A., Graham, J., Quirke, P., Richman, S. D., Butler, R., Domingo, E., Blake, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01435 · Cited by 117 · cited 4×
“Adavosertib WEE1 mCRC RAS, TP53 FOCUS4-C II [44]”
BackgroundInfluentialZimmer, A. S., Nichols, E., Cimino-Mathews, A., Peer, C., Cao, L., Lee, M.-J., Kohn, E. C., Annunziata, C. M., Lipkowitz, S., Trepel, J. B., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0680-3 · Cited by 113 · cited 2×
“Olaparib PARP Durvalumab PD-L1 Cediranib (VEGF) Solid tumors NCT02484404 I/II [15,127]”
BackgroundCao, X., Liang, Y., Hu, Z., Li, H., Yang, J., Hsu, E. J., Zhu, J., Zhou, J., & Fu, Y. (2021) · Nature Communications · doi:10.1038/s41467-021-26112-2 · Cited by 111 · cited 1×
“IFNs can increase specific immunity against primary tumors, enhance DC cross-priming and increase infiltration and effector function of CD8+ T cells in the tumor microenvironment [85].”
BackgroundRizzo, A., & Brandi, G. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100328 · Cited by 103 · cited 1×
“For example, deficiency in BRCA1 or BRCA2 gene is observed to be associated with improved response to ICIs in patients with biliary tract cancer or hepatocellular carcinoma [16,17].”
BackgroundAbbotts, R., Topper, M. J., Biondi, C., Fontaine, D., Goswami, R., Stojanovic, L., Choi, E. Y., McLaughlin, L. J., Kogan, A. A., Xia, L., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903765116 · Cited by 100 · cited 1×
“Inhibition of DNA methyltransferase results in HRD phenotype and sensitizes BRCA-proficient NSCLC cells to PARP inhibitors [151].”
BackgroundInterfaces between cellular responses to DNA damage and cancer immunotherapy
Pilger, D., Seymour, L. W., & Jackson, S. P. (2021) · Genes & Development · doi:10.1101/gad.348314.121 · Cited by 95 · cited 2×
“These IFN-induced immune responses are crucial for the killing of cancer cells; thus, IFN response induced by DDR targeting (PARPness) can enhance the efficacy of cancer immunotherapy [80,81].”
BackgroundWEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry
Elbæk, C. R., Petrosius, V., & Sørensen, C. S. (2020) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2020.111694 · Cited by 94 · cited 1×
“In contrast to the role of CDC25 in CDK1 activation, the WEE1 kinase phosphorylates and inactivates CDK1; therefore, the cell cycle progression from G2 to M phase is inhibited [43] (Figure 2B).”
BackgroundAdams, S., Dieras, V. C., Barrios, C. H., Winer, E. P., Schneeweiß, A., Iwata, H., Loi, S., Patel, S., Henschel, V., Chui, S. Y., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.003 · Cited by 94
Genetics of familial and sporadic pancreatic cancer
Wood, L. D., Yurgelun, M. B., & Goggins, M. G. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.039 · Cited by 91 · cited 1×
“Whole-exome and whole-genome sequencing of PDAC have confirmed alterations in the critical driver genes in the majority of pancreatic cancers [49,133].”
BackgroundThe DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer
Mauri, G., Arena, S., Siena, S., Bardelli, A., & Sartore-Bianchi, A. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.027 · Cited by 86 · cited 2×
“The sensitivity of PARP inhibitor are observed in cancer patients who are sensitive to platinum drugs or radiotherapy [73].”
BackgroundThe DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora’s box?
Ricci, A. D., Rizzo, A., & Brandi, G. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-001042 · Cited by 83 · cited 1×
“For example, deficiency in BRCA1 or BRCA2 gene is observed to be associated with improved response to ICIs in patients with biliary tract cancer or hepatocellular carcinoma [16,17].”
BackgroundYarchoan, M., Myzak, M. C., Johnson, B. A., De Jesus-Acosta, A., Le, D. T., Jaffee, E. M., Azad, N. S., Donehower, R. C., Zheng, L., Oberstein, P. E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17237 · Cited by 77 · cited 3×
“Combination Elimusertib ATR Irinotecan aPC 7, SCLC 8 PD-NEC 9 NCT04514497 I DDRi+CT/RT Elimusertib ATR Topotecan Peposertib DNA-PK Hypofractionated RT localized aPC NCT04172532 I/II [70] Olaparib PARP Irinotecan, Cisplatin, Mitomycin aPC BRCA/FANC, HRD NCT01296763 I [138]”
BackgroundATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications
Armstrong, S. A., Schultz, C. W., Azimi-Sadjadi, A., Brody, J. R., & Pishvaian, M. J. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0208 · Cited by 73 · cited 1×
“Somatic mutations of BRCA1, BRCA2 and PALB2 are ~14% in pancreatic cancer [134,135].”
BackgroundCXCL10 potentiates immune checkpoint blockade therapy in homologous recombination-deficient tumors
Shi, Z., Shen, J., Qiu, J., Zhao, Q., Hua, K., & Wang, H. (2021) · Theranostics · doi:10.7150/thno.59056 · Cited by 72
Khaddour, K., Jonna, S., Deneka, A. Y., Patel, J. D., Abazeed, M. E., Golemis, E. A., Borghaei, H., & Boumber, Y. (2021) · Cancers · doi:10.3390/cancers13133164 · Cited by 71 · cited 1×
“For examples, cell growth and angiogenesis signalings mediated by epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) pathways are identified as the main molecular targets of tyrosine kinase inhibitors (TKIs) (Figure 1B) [4,5].”
BackgroundRAD51C Germline Mutations in Breast and Ovarian Cancer Cases from High-Risk Families
Clague, J., Wilhoite, G., Adamson, A., Bailis, A., Weitzel, J. N., & Neuhausen, S. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025632 · Cited by 71
Role of DNA repair defects in predicting immunotherapy response
Zhang, J., Shih, D. J. H., & Lin, S.-Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-00202-7 · Cited by 69
Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma
Seeber, A., Zimmer, K., Kocher, F., Puccini, A., Xiu, J., Nabhan, C., Elliott, A., Goldberg, R. M., Grothey, A. F., Shields, A. F., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000942 · Cited by 56 · cited 1×
“Somatic mutations of BRCA1, BRCA2 and PALB2 are ~14% in pancreatic cancer [134,135].”
BackgroundSeyedin, S. N., Hasibuzzaman, M. M., Pham, V., Petronek, M. S., Callaghan, C. M., Kalen, A. L., Mapuskar, K. A., Mott, S. L., Spitz, D. R., Allen, B. G., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.01.030 · Cited by 56 · cited 1×
“These DDR features are good biomarkers for cancer immunotherapy and may be ideal targets of DDR inhibitors [125].”
BackgroundCalegari, M. A., Inno, A., Monterisi, S., Orlandi, A., Santini, D., Basso, M., Cassano, A., Martini, M., Cenci, T., Pascalis, I. D., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.109 · Cited by 55 · cited 1×
“The TMZ alone does not gain promising clinical benefit in CRC [132].”
BackgroundKu70/80 Modulates ATM and ATR Signaling Pathways in Response to DNA Double Strand Breaks
Tomimatsu, N., Tahimic, C. G. T., Otsuki, A., Burma, S., Fukuhara, A., Sato, K., Shiota, G., Oshimura, M., Chen, D. J., & Kurimasa, A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611880200 · Cited by 54
Wang, H., Ma, H., Sové, R. J., Emens, L. A., & Popel, A. S. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002100 · Cited by 53 · cited 1×
“This indicates that before immunotherapy, the personalize gene analyzed is important [118,119].”
BackgroundDNA Repair and Ovarian Carcinogenesis: Impact on Risk, Prognosis and Therapy Outcome
Tomášová, K., Čumová, A., Šeborová, K., Horak, J., Koucká, K., Vodičková, Ľ., Václavíková, R., & Vodička, P. (2020) · Cancers · doi:10.3390/cancers12071713 · Cited by 52
Going to extremes: determinants of extraordinary response and survival in patients with cancer
Saner, F. A. M., Herschtal, A., Nelson, B. H., deFazio, A., Goode, E. L., Ramus, S. J., Pandey, A., Beach, J. A., Fereday, S., Berchuck, A., et al. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0145-5 · Cited by 51 · cited 1×
“It is worthy to investigate the genetic, epigenetic, and functional statuses of DDR and immune genes in the tumors of these “exceptional responders”, which may shed light on new directions for the development of cancer therapy [148].”
BackgroundTakeuchi, S., Doi, M., Ikari, N., Yamamoto, M., & Furukawa, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-26526-x · Cited by 50 · cited 1×
“Rucaparib PARP Irinotecan Fluorouracil, Leucovorin mPC, CRC BRCA1/2, PALB2 (HRD 11) NCT03337087 I/II [141]”
Pishvaian, M. J., Wang, H., He, A. R., Hwang, J. J., Smaglo, B. G., Kim, S. S., Weinberg, B. A., Weiner, L. M., Marshall, J. L., & Brody, J. R. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1301 · Cited by 48 · cited 2×
“The results suggest that combination of veliparib and FOLFOX is effective in patients harboring HRD mutations [140].”
BackgroundWang, Y., Zheng, K., Xiong, H., Huang, Y., Chen, X., Zhou, Y., Qin, W., Su, J., Chen, R., Qiu, H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.762989 · Cited by 48 · cited 1×
“have shown that the treatment of PARP inhibitor pamiparib increases PD-L1 expression in pancreatic cancer cells and the combination of pamiparib and PD-L1 mAb improved therapeutic efficacy when compared to monotherapy [100].”
BackgroundHaines, E., Nishida, Y., Carr, M. I., Montoya, R. H., Ostermann, L. B., Zhang, W., Zenke, F. T., Blaukat, A., Andreeff, M., & Vassilev, L. T. (2021) · Scientific Reports · doi:10.1038/s41598-021-90500-3 · Cited by 39 · cited 3×
“Combination Elimusertib ATR Irinotecan aPC 7, SCLC 8 PD-NEC 9 NCT04514497 I DDRi+CT/RT Elimusertib ATR Topotecan Peposertib DNA-PK Hypofractionated RT localized aPC NCT04172532 I/II [70] Olaparib PARP Irinotecan, Cisplatin, Mitomycin aPC BRCA/FANC, HRD NCT01296763 I [138]”
BackgroundYang, C., Zhang, Z., Tang, X., Zhang, X., Chen, Y., Hu, T., Zhang, H., Guan, M., Zhang, X., & Wu, Z. (2021) · Human Cell · doi:10.1007/s13577-021-00630-z · Cited by 38
Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era
Macedo, G. S., Alemar, B., & Ashton‐Prolla, P. (2019) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2018-0104 · Cited by 29
Gong, Z., Yang, Y., Zhang, J., & Guo, W. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0351 · Cited by 12 · cited 1×
“Thus, DDR alterations are useful biomarkers for choosing the patients to receive ICB therapy [106,107].”
BackgroundDickson, K.-A., Xie, T., Evenhuis, C., Ma, Y., & Marsh, D. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168506 · Cited by 11
Targeting DNA Homologous Repair Proficiency With Concomitant Topoisomerase II and c-Abl Inhibition
Siddiqui, A., Tumiati, M., Joko, A., Sandholm, J. A., Roering, P., Aakko, S., Vainionpää, R., Kaipio, K., Huhtinen, K., Kauppi, L., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.733700 · Cited by 11 · cited 1×
“Therefore, combination of PARP and BRD4 inhibitors can induce synthetic lethality in HR-proficient cancers [67,68].”
BackgroundTargeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma
Das, S., & Cardin, D. B. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00763-7 · Cited by 9 · cited 1×
“PARP inhibitors in combination with platinum chemotherapy elicit a higher response rate in advanced pancreatic cancer patients than chemotherapy alone [74].”
BackgroundDNA repair sleuths win chemistry Nobel
Cressey, D. (2015) · Nature · doi:10.1038/nature.2015.18515 · Cited by 9 · cited 1×
“In 2015, the Nobel Prize in chemistry was awarded to Tomas Lindahl, Paul Modrich and Aziz Sancar “for mechanistic studies of base excision repair (BER), mismatch repair (MMR) and nucleotide excision repair (NER)”, respectively [30].”
MethodLoRusso, P. M., Pilat, M. J., Santa-Maria, C. A., Connolly, R. M., Roesch, E. E., Afghahi, A., Han, H. S., Nanda, R., Wulf, G. M., Assad, H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.tps1102 · Cited by 9 · cited 1×
“Combination Olaparib PARP Durvalumab PD-L1 Metastatic HER2- BC 1 Germline BRCAm 2 NCT02734004 II MEDIOLA trial [109] Niraparib PARP Pembrolizumab PD-1 aTNBC 3 or mTNBC 4 BRCAm NCT02657889 II TOPACIO trial [111] Talazoparib PARP Avelumab PD-L1 aBC 5 NCT03964532 I/II TALAVE trial [112] Olaparib PARP Atezolizurmab PD-L1…”
BackgroundERCC1 Is a Predictive Biomarker for Non-small Cell Lung Cancer But Is Antibody-dependent
Okimoto, T., Tsubata, Y., Tanino, R., Nakao, M., Hotta, T., Hamaguchi, M., Hamaguchi, S., Araki, A., & Isobe, T. (2021) · Anticancer Research · doi:10.21873/anticanres.15046 · Cited by 7 · cited 1×
“In NSCLC, low expression of ERCC1 predicts a better outcome in patients who receive platinum-based chemotherapy due to inefficient NER and increased apoptosis of tumor cells [33,34].”
Background
Cited by
Besse, B., Tostivint, E. P., Park, K., Hartl, S., Forde, P. M., Hochmair, M. J., Awad, M. M., Thomas, M., Goss, G. D., Wheatley‐Price, P., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02808-y · Cited by 200
“Mismatch repair deficiency is associated with greater benefit from immunotherapies 31–34 ; HUDSON therefore evaluated inhibitors of DNA damage response (DDR) and repair pathways in combination with the anti-PD-L1 monoclonal antibody durvalumab.”
The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
Shi, C., Qin, K., Lin, A., Jiang, A., Cheng, Q., Liu, Z., Zhang, J., & Luo, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02469-0 · Cited by 85
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Defective DDR can also cause changes in the TME by releasing inflammatory cytokines, which create an immunosuppressive state that helps CRC cells evade immune surveillance, thereby reducing the effectiveness of immunotherapies [51].”
InfluentialNew Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives
Previtali, V., Bagnolini, G., Ciamarone, A., Ferrandi, G., Rinaldi, F., Myers, S. H., Roberti, M., & Cavalli, A. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00113 · Cited by 87
PD-1/PD-L1 and DNA Damage Response in Cancer
Kciuk, M., Kołat, D., Kałuzińska‐Kołat, Ż., Gawrysiak, M., Drozda, R., Çelik, İ., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040530 · Cited by 50
“The detection of cytosolic DNA by PRRs initiates IFNγ signaling and accompanying innate and adaptive immune responses, similarly as in the case of DAMPs, facilitating the anti-tumor immune response [228].”
Background
Metadata
- Authors
- Huang, J.-L., Chang, Y.-T., Hong, Z.-Y., & Lin, C.-S.
- Affiliations
- Chang Jung Christian University (TW)
- National Sun Yat-sen University (TW)
- Corresponding author
- Lin, Chang-Shen
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-03-17
- Volume
- 23
- Issue
- 6
- Pages
- 3238
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8952261
- OpenAlex
- W4221000214
- Cited by
- 42
- References
- 154
- Citations by year
- 2026: 7 · 2025: 15 · 2024: 6 · 2023: 8 · 2022: 6
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Ministry of Science and Technology, Taiwan (108-2635-B-309-001 and 110-2320-B-037-023. The APC was funded by 110-2320-B-037-023”)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- DNA damage response, immune checkpoint blockade, synthetic lethality, cancer immunotherapy, cGAS-STING pathway, interferon signaling, genomic instability, breast cancer, colorectal cancer, pancreatic cancer
- MeSH terms
- DNA Damage, DNA Repair, Humans, Immunity, Immunotherapy, Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.